Key result
The R1512W mutation reduced sodium current expression by ~50% compared to wild-type channels, which was restored by mexiletine and the H558R polymorphism.
Why the study?
Mutations in SCN5A reducing Na current cause arrhythmia syndromes like Brugada syndrome, but the effect of SCN5A splice variant background on loss-of-function and rescue for the R1512W mutation was unknown.
Does mexiletine or the H558R polymorphism rescue the expression defect of the R1512W mutation in SCN5A splice variants?
Does mexiletine or the H558R polymorphism rescue the expression defect of the R1512W mutation in SCN5A splice variants?
Mexiletine and the H558R polymorphism can rescue the loss-of-function expression defect of the Brugada syndrome-associated R1512W mutation in SCN5A.
Answers are grounded in this paper and cite their sources.
Mexiletine may rescue R1512W trafficking defects in Brugada models; leaves open clinical translation and patient outcomes.
Background: Mutations in SCN5A that decrease Na current underlie arrhythmia syndromes such as the Brugada syndrome (BrS). SCN5A in humans has two splice variants, one lacking a glutamine at position 1077 (Q1077del) and one containing Q1077. We investigated the effect of splice variant background on loss-of-function and rescue for R1512W, a mutation reported to cause BrS.Methods and results: We made the mutation in both variants and expressed them in HEK-293 cells for voltage-clamp study. After 24 hours of transfection, the current expression level of R1512W was reduced by ~50% in both Q1077del and Q1077 compared to the wild-type (WT) channel, respectively. The activation and inactivation midpoint were not different between WT and mutant channels in both splice variant backgrounds. However, slower time constants of recovery and enhanced intermediate inactivation were observed for R1512W/Q1077 compared with WT-Q1077, while the recovery and intermediate inactivation parameters of R1512W/Q1077del were similar to WT-Q1077del. Furthermore, both mexiletine and the common polymorphism H558R restored peak sodium current (INa) amplitude of the mutant channel by increasing the cell surface expression of SCN5A.Conclusion: These findings provide further evidence that the splice variant affects the molecular phenotype with implications for the clinical phenotype, and they provide insight into the expression defect mechanisms and potential treatment in BrS.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2021) studied Brugada syndrome. R1512W mutation, mexiletine, and H558R polymorphism vs. Wild-type (WT) channel was evaluated on Current expression level and peak sodium current (INa) amplitude. The R1512W mutation reduced sodium current expression by ~50% compared to wild-type channels, which was restored by mexiletine and the H558R polymorphism.
Synapse has enriched 10 related papers. Consider them for comparative context: